Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971940 | 0.86 | RORC (0.49) | RORCNR3C1PGRROCK2ROCK1 | |
| SCHEMBL18664430 | 0.79 | PPARA (0.56) | NAMPTL3MBTL1HDAC1EGLN2 | |
| SCHEMBL3274015 | 0.77 | EPHX2 (0.58) | NAMPTL3MBTL1HDAC1 | |
| SCHEMBL2004916 | 0.75 | RORC (0.46) | RORCNR3C1PGRCTSANSD2 | |
| SCHEMBL6959964 | 0.74 | PTPN1 (0.57) | NAMPTL3MBTL1GRM2HDAC1NSD2 | |
| SCHEMBL7167358 | 0.73 | KDM4E (0.53) | NAMPTL3MBTL1GRM2DYRK1AATR | |
| SCHEMBL25173962 | 0.73 | HDAC1 (0.46) | NAMPTL3MBTL1GRM2HDAC1 | |
| SCHEMBL23949875 | 0.73 | NSD2 (0.42) | NAMPTL3MBTL1GRM2HDAC1NSD2 | |
| SCHEMBL20757726 | 0.72 | EGLN2 (0.42) | NAMPTL3MBTL1NSD2EGLN2 | |
| SCHEMBL595225 | 0.72 | CA12 (0.52) | NAMPTL3MBTL1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | RORC 144/4885NAMPT 4461/4885NR3C1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.